8-K: Microbot Medical Secures Nearly $3 Million from Preferred Option Exercises

Microbot Medical Inc. announced the exercise of Series G and Series F preferred investment options, generating approximately $2.975 million in gross proceeds.

Summary

• Microbot Medical Inc. issued an aggregate of 1,808,336 shares of common stock since June 18, 2025.
• This issuance resulted from the exercise of 1,025,000 Series G preferred investment options and 783,336 Series F preferred investment options.
• The Series G options were exercised at $1.75 per share, yielding approximately $1.8 million in gross proceeds.
• The Series F options were exercised at $1.50 per share, yielding approximately $1.175 million in gross proceeds.
• Total gross proceeds from these exercises amounted to approximately $2.975 million, before deducting placement agent fees and expenses.
• The shares were issued under the exemption provided in Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions not involving a public offering.
• Shares underlying both Series G and Series F options were registered for resale on Form S-3 registration statements (No.: 333-284688 for Series G and No.: 333-280113 for Series F).

Sentiment

Score: 6

Explanation: The filing reports a successful capital inflow from the exercise of existing preferred investment options, strengthening the company's cash position, which is a positive for liquidity.

Positives

• Generated approximately $2.975 million in gross proceeds from the exercise of preferred investment options, enhancing the company's cash position.
• The exercise of options indicates investor confidence and commitment from existing holders.

Future Outlook

The document does not provide specific forward-looking statements or guidance beyond the reported transaction.

Management Comments

• The report was signed by Harel Gadot, Chief Executive Officer, President and Chairman.

Industry Context

This filing reports a routine capital transaction for a publicly traded medical device company, common for companies seeking to bolster their balance sheet or as part of pre-existing financing agreements. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The exercise of options leads to an increase in the number of outstanding common shares, which could result in dilution for existing shareholders, although the capital inflow strengthens the company's financial position.

Key Dates

Keywords

Microbot Medical, MBOT, Equity Issuance, Preferred Options, Capital Raise, SEC Filing, 8-K, Common Stock, Investment Options